ClinicalTrials.gg
CompletedNCT03643016EPINOVUpdated Nov 20, 2026

Improving EPilepsy Surgery Management and progNOsis Using Virtual Epileptic Patient Software (VEP)

An interventional study of Surgical strategy based on a software in Epilepsy, sponsored by Assistance Publique Hopitaux De Marseille. Completed at 1 site in France. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Other

How we know

Updated Nov 20, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
356
Allocation
Randomized
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Epilepsy by Assistance Publique Hopitaux De Marseille — 6 open to participants now, 7 under way, none of them phase 3. Epilepsy · Assistance Publique Hopitaux De Marseille.

Enrollment
Largest of 15
356 · median 60
Started
2019
with 1 other
No phase
15 of 18
3 open now
Registered
5th of 18
by date

Among the 18 studies in Epilepsy by Assistance Publique Hopitaux De Marseille, this one has the largest enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2019, is one of 15 with no phase, and was the 5th registered.

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

Browse Epilepsy studies →

Open to participants now

6 of the 18 studies in Epilepsy by Assistance Publique Hopitaux De Marseille are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Epilepsy by Assistance Publique Hopitaux De Marseille, or all of them as a file.
02

Study summary

Every year, thousands of patients worldwide with drug resistant focal epilepsy (DRE) undergo resective brain surgery with the aim of achieving seizure freedom.

Despite technical advances over the last 50 years, the success rate of epilepsy surgery in terms of seizure freedom has not greatly improved, remaining overall at around 50%. Depending on features of individual cases, presurgical evaluation includes a first phase of non-invasive data including video-EEG recordings, magnetoencephalography, structural and functional neuroimaging and neuropsychological evaluation. If these investigations do not allow adequate localization of likely region of seizure organization in the brain (the epileptogenic zone, EZ), then a second invasive phase using intracerebral EEG recording may be necessary (stereoelectroencephalography, SEEG). Interpretation of SEEG remains difficult in many cases, in particular since seizure onset is often characterized by discharges that very rapidly involve several distinct brain regions.

No reliable measuring instrument currently exists to combine the various prognostic factors for a given patient. This leads to great uncertainty on an individual scale in predicting the effects of surgery. The mapping of epileptic networks in patients with DRE is an innovative scientifically-validated and clinically-tested method to significantly improve accuracy of SEEG and presurgical interpretation and guide surgical strategies in patients with DRE. Therefore, the investigators developed the Virtual Epilepsy Patient software. Retrospective study already demonstrated the pertinence of this approach in improving the anatomical mapping of epileptogenic networks. Now, the investigators aim to prospectively demonstrate the role of VEP during presurgical evaluation of DRE patients

03

Conditions studied

  • Epilepsy

Browse trials for

04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient or pediatric patient suffering from drug-resistant focal epilepsy.
  • Standardized presurgical evaluation including medical history, scalp video-EEG, 3T MRI (DTI and rsMRI), FDG-PET, Neuropsychological tests.
  • Inpatient in one of the participating centers for recording seizure during long term SEEG-monitoring.

Exclusion criteria

Exclusion Criteria:

  • Epilepsy surgery performed without the requirement of SEEG or to epilepsy surgery.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
356 participants (actual)

Study arms

  • Experimental
    Group with Virtual Epileptic Patient brain access data

    Other: Surgical strategy based on a software

  • No intervention
    Group without Virtual Epileptic Patient brain access data

Interventions

  • OtherSurgical strategy based on a software

    Surgical strategy décision based on a software

06

What researchers measure

Primary outcomes

  1. Clinical success, defined as seizure free patient without disabling side effect (clinical judgment) at 12-month follow-up

    Number of seizure (Engel I)

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Jun 2023, 47 months.

Of 339 non-industry interventional studies with no phase under Epilepsy, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 77. This study's 47 months is close to that.

Counting every sponsor, half of 360 studies reached it within 42 months; a quarter within 19 and three quarters within 77.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Dec 2024 → Jun 2023 and completion Dec 2025 → Jun 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2018
First posted
Aug 22, 2018
StartActual
Jun 26, 2019
Primary completionActual
Jun 12, 2023was Dec 2024
CompletionActual
Jun 12, 2023was Dec 2025
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 20, 2026
Primary completion
Dec 23, 2024→Jun 12, 2023 (actual)
Nov 20, 2026
Study completion
Dec 23, 2025→Jun 12, 2023 (actual)
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Recruiting→Completed
    Primary completion Dec 23, 2024→Jun 12, 2023 (now actual)
    Study completion Dec 23, 2025→Jun 12, 2023 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03643016
Responsible party
Sponsor
First posted
Aug 22, 2018
Start date
Jun 26, 2019
Primary completion
Jun 12, 2023
Completion
Jun 12, 2023
Last update
Nov 20, 2026

Study contacts

Emilie Garrido-Pradalié
study director · Assitance Publique Hôpitaux de Marseille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion